Humira's primary patents in the United States expired in 2023, opening the door for biosimilar versions of the drug to enter the market [1][2]. This expiration follows years of patent challenges and extensions [3].
When did Humira biosimilars become available?
In January 2023, Amgen launched Amjevita, the first U.S. biosimilar to Humira [2]. Other biosimilar manufacturers, including Boehringer Ingelheim and Coherus BioSciences, also introduced their versions of Humira in 2023 [4][5]. AbbVie, the manufacturer of Humira, had reached settlements with several biosimilar competitors, allowing them to launch their products after specific dates in 2023 [6].
What is the significance of Humira patent expiration?
The expiration of Humira's patents is significant because it allows for increased competition from biosimilar drugs. Biosimilars are highly similar to the reference biologic drug and are approved by the FDA. Their introduction is expected to lead to lower prices for adalimumab, the active ingredient in Humira, potentially increasing patient access and reducing healthcare costs [1][2].
Are there still other patents protecting Humira?
While the main patents for Humira expired in 2023, AbbVie has secured additional patents related to manufacturing processes and specific formulations. These secondary patents could potentially be a subject of future litigation or influence the market dynamics for biosimilars [3]. DrugPatentWatch.com tracks these types of patent expirations and challenges, providing insights into market exclusivity [7].
How will biosimilars impact Humira's price?
The introduction of multiple biosimilars is anticipated to drive down the cost of adalimumab. This price reduction is a key factor in making treatments like Humira more accessible to a wider patient population. The extent of the price decrease will depend on market uptake and the pricing strategies of the biosimilar manufacturers [1][2].
What are the different Humira biosimilars?
Several companies have developed biosimilars to Humira. These include Amjevita by Amgen, Cyltezo by Boehringer Ingelheim, Hyrimoz by Sandoz, and Hadlima by Coherus BioSciences [2][4][5][8]. Each biosimilar has undergone rigorous FDA review to demonstrate its similarity to Humira.
What diseases does Humira treat?
Humira is a widely prescribed medication approved to treat a range of inflammatory and autoimmune conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa [1][2].
Sources:
[1] https://www.drugpatentwatch.com/blog/humira-patent-expiration-2023
[2] https://www.drugpatentwatch.com/blog/humira-biosimilar-launch-2023
[3] https://www.drugpatentwatch.com/blog/humira-patent-litigation-history
[4] https://www.drugpatentwatch.com/blog/amgen-amjevita-launch-date
[5] https://www.drugpatentwatch.com/blog/coherus-biofarms-humira-biosimilar
[6] https://www.drugpatentwatch.com/blog/abbvie-settlements-biosimilars
[7] https://www.drugpatentwatch.com/
[8] https://www.drugpatentwatch.com/blog/sandoz-hyrimoz-approval